Frederick Locke, MD, discuss 2 allogeneic CD19-directed chimeric antigen receptor T-cell agents for the treatment of relapsed or refractory large B-cell lymphoma.
Frederick Locke, MD, a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, explains the allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapies, ALLO-501 and ALLO-501A, and how they work.
An investigation of ALLO-501A for the treatment of patients with large B-cell lymphoma is occurring in the phase 2 ALPHA2 study (NCT04416984), which aims to include 100 patients. Patients in the study will be treated with ALLO-501A in addition to ALLO-647 and lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide. The key end point being assessed is objective response rate (ORR).
ALLO-501A is an identical drug to ALLO-501, says Locke. The one difference between the agents is that ALLO-501A has no rituximab (Rituxan) kill switch. Both agents have a gene editing component, which allows for each agent to be used in combination with chemotherapy and a CD52-directed CAR T product, according to Locke.
0:08 | ALLO-501 and ALLO-501A are off-the-shelf allogeneic CD19-directed CAR T-cell therapies. The only difference between ALLO-501 and ALLO-501A is that ALLO-501A has removed a rituximab kill switch, which was present in ALLO-501. Otherwise, they're identical. These CAR T cells have gene editing. So, not only do they express the CD19 CAR, but their gene-edited. The track locus is removed so that the T cell receptor is not expressed and therefore, the cells are unlikely to cause graft-versus-host disease.
0:56 | The CAR T cells are gene-edited so that CD52, which is a cell surface protein that's on immune cells, is removed from the CAR T cells and that actually allows us to also give an antibody against CD52 as part of the conditioning chemotherapy regimen, which ALLO-647. It's a monoclonal antibody against CD52, which has been removed from those CAR T cells.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More